CA2855298A1 - Her3 antibodies and uses thereof - Google Patents

Her3 antibodies and uses thereof Download PDF

Info

Publication number
CA2855298A1
CA2855298A1 CA2855298A CA2855298A CA2855298A1 CA 2855298 A1 CA2855298 A1 CA 2855298A1 CA 2855298 A CA2855298 A CA 2855298A CA 2855298 A CA2855298 A CA 2855298A CA 2855298 A1 CA2855298 A1 CA 2855298A1
Authority
CA
Canada
Prior art keywords
antibody
her3
seq
subject
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2855298A
Other languages
English (en)
French (fr)
Inventor
Tong Zhou
Donald J. Buchsbaum
Enyun Shen
Xian Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Cotimes Biotech Co Ltd
UAB Research Foundation
Original Assignee
Beijing Cotimes Biotech Co Ltd
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Cotimes Biotech Co Ltd, UAB Research Foundation filed Critical Beijing Cotimes Biotech Co Ltd
Publication of CA2855298A1 publication Critical patent/CA2855298A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2855298A 2011-11-09 2012-11-09 Her3 antibodies and uses thereof Abandoned CA2855298A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557672P 2011-11-09 2011-11-09
US61/557,672 2011-11-09
PCT/US2012/064381 WO2013071058A1 (en) 2011-11-09 2012-11-09 Her3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA2855298A1 true CA2855298A1 (en) 2013-05-16

Family

ID=48290585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2855298A Abandoned CA2855298A1 (en) 2011-11-09 2012-11-09 Her3 antibodies and uses thereof

Country Status (7)

Country Link
US (1) US9637543B2 (enExample)
EP (1) EP2788377B1 (enExample)
JP (1) JP6149042B2 (enExample)
CN (1) CN104011079B (enExample)
AU (1) AU2012335543C1 (enExample)
CA (1) CA2855298A1 (enExample)
WO (1) WO2013071058A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
WO2013078191A1 (en) 2011-11-23 2013-05-30 Medimmune, Llc Binding molecules specific for her3 and uses thereof
ES2758433T3 (es) * 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) * 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
CN110366563A (zh) * 2016-12-22 2019-10-22 西奈山伊坎医学院 抗lilrb3抗体及其使用方法
JP2024523885A (ja) * 2021-06-15 2024-07-02 ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド 抗ｈｅｒ３抗体、それを含有する抗体薬物複合体及びそれらの用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
PT896586E (pt) * 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
AUPP380498A0 (en) 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
CA2771744A1 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
PH12013500333A1 (en) * 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
JP5995851B2 (ja) * 2010-10-18 2016-09-21 メディアファーマ エス． アール． エル．Ｍｅｄｉａｐｈａｒｍａ Ｓ． Ｒ． Ｌ． ＥｒｂＢ３結合抗体

Also Published As

Publication number Publication date
EP2788377B1 (en) 2019-01-23
WO2013071058A1 (en) 2013-05-16
AU2012335543A8 (en) 2014-06-26
EP2788377A1 (en) 2014-10-15
JP6149042B2 (ja) 2017-06-14
CN104011079B (zh) 2017-06-16
EP2788377A4 (en) 2015-11-18
JP2014533278A (ja) 2014-12-11
AU2012335543C1 (en) 2017-12-14
US9637543B2 (en) 2017-05-02
US20140314774A1 (en) 2014-10-23
AU2012335543B2 (en) 2017-08-24
CN104011079A (zh) 2014-08-27
AU2012335543A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
US9637543B2 (en) HER3 antibodies and uses thereof
TWI848090B (zh) 密蛋白抗體及其應用
ES2429340T3 (es) Anticuerpos anti-mesotelina
ES2906823T3 (es) Anticuerpos agonistas que se unen específicamente a CD40 humano y métodos de uso
AU2013266611B2 (en) Methods for improving safety of blood-brain barrier transport
EP4151652A1 (en) Anti-cd73 antibody and use thereof
CN109195991A (zh) 对糖基化pd-l1特异的双重功能抗体及其使用方法
BR112013004012B1 (pt) Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
CA2966365A1 (en) Blood brain barrier receptor antibodies and methods of use
TW201815823A (zh) 抗－pd－1抗體
EP4056586A1 (en) Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto
RU2704228C2 (ru) Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения
CN117529337A (zh) 针对dll3的结合分子及其应用
JP2020518668A (ja) ｘＣＴ抗体に関連する組成物および方法
CN110386981A (zh) 抗gitr抗体及其用途
US10465004B2 (en) Frizzled receptor antibodies for treatment of cancer
EP3768711B1 (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
RU2653443C2 (ru) Биспецифичные анти-her2/анти-her3 антитела
KR20220110522A (ko) 항gdf15 항체
TWI703155B (zh) 特異性結合至ｐａｕｆ蛋白質的抗體及其用途
HK40083261A (en) Anti-cd73 antibody and use thereof
HK40045294B (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
HK40045294A (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
EA043217B1 (ru) Анти-cd137 антитела
HK40025609A (en) Antibody specifically binding to pauf protein and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170815

FZDE Discontinued

Effective date: 20191112